Idecabtagene vicleucel
Gene therapy medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Abecma?
Summarize this article for a 10 year old
Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma.[4][8]
Gene therapy | |
---|---|
Target gene | TNFRSF17 |
Clinical data | |
Trade names | Abecma |
Other names | bb2121 |
AHFS/Drugs.com | Abecma |
License data | |
Routes of administration | Intravenous |
Drug class | Antineoplastic |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
UNII | |
KEGG |
The most common side effects include cytokine release syndrome (CRS), infections, fatigue, musculoskeletal pain, and a weakened immune system (hypogammaglobulinemia).[4][5]
Idecabtagene vicleucel is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy.[4][5] Each dose is customized using a patient's own T-cells, which are a type of white blood cell, that are collected and genetically modified to include a new gene that facilitates targeting and killing myeloma cells, and infused back into the patient.[4][5]
Idecabtagene vicleucel was approved for medical use in the United States in March 2021.[3][4][5] It is the first cell-based gene therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.[4][5] It was approved for medical use in the European Union in August 2021.[6][9]